ChunLei Ge

Dr. ChunLei Ge

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
CGChunLei Ge
ChunLei Ge
RLRuilei Li
Ruilei Li
HSHaifeng Song
Haifeng Song
TGTao Geng
Tao Geng
JYJinyan Yang
Jinyan Yang
XSXin Song
Xin Song
The primary aim of this study was to evaluate the safety of a novel dendritic cell (DC) vaccine pulsed with survivin and MUC1, silenced with suppressor of cytokine signaling 1 (SOCS1), and immune stimulated with flagellin for patients with stage I to IIIA non-small cell lung cancer (NSCLC) in a phase I open-label, uncontrolled, and dose-escalation trial. Moreover, we evaluate the potential efficacy of this modified DC vaccine as secondary aim. The patients were treated with the vaccine at 1 × 106, 1 × 107and the maximum dose 8 × 107 at day 7, 14, and 21 after characterization of the vaccine phenotype by flow cytometry. The safety of the vaccine was assessed by adverse events, and the efficacy by the levels of several specific tumor markers and the patient quality of life. The vaccine was well tolerated without dose-limiting toxicity even at higher doses. The most common adverse event reported was just grade 1 flu-like symptoms without unanticipated or serious adverse event. A significant decrease in CD3 + CD4 + CD25 + Foxp3+ T regulatory (Treg) cell number and increase in TNF-α and IL-6 were observed in two patients. Two patients showed 15% and 64% decrease in carcino-embryonic antigen and CYFRA21, respectively. The vaccination with the maximum dose significantly improved the patients’quality of life when administered at the highest dose. More importantly, in the long-term follow-up until February 17, 2017, 1 patient had no recurrence, 1 patients had a progressive disease (PD), and 1 patient was died in the low dose group. In the middle dose group, all 3 patients had no recurrence. In the high dose group, 1 patient was died, 1 patient had a PD, and the other 7 patients had no recurrence. We provide preliminary data on the safety and efficacy profile of a novel vaccine against non-small cell lung cancer, which was reasonably well tolerated, induced modest antitumor activity without dose-limiting toxicity, and improved patients’ quality of life. Further more, the vaccine maybe a very efficacious treatment for patients with resected NSCLC to prevent recurrence. Our findings on the safety and efficacy of the vaccine in this phase I trial warrant future phase II/III clinical trial.

1 January 2025 in Oncology Research
Verified
Journal Article
Open access
PDF file
YFYi Feng
Yi Feng
HYHaoxin Yang
Haoxin Yang
GLGuicai Liang
Guicai Liang
JCJun Chen
Jun Chen
TLTao Li
Tao Li
CGChunLei Ge
ChunLei Ge
Immune checkpoint inhibitor (ICI) has limited efficacy in the treatment of immune “cold” tumors. Due to insufficient T cell infiltration and heterogeneous programmed death ligand 1 (PD-L1) expression, the ORR is only 5%–8% compared with 30%–40% of “hot” tumors. This article reviews the synergistic mechanism, clinical efficacy and optimization strategy of oncolytic virus (OVs) combined with ICIs in the treatment of refractory malignant tumors. Systematic analysis of mechanistic interactions across tumor types and clinical trial data demonstrates that OVs transform the immunosuppressive microenvironment by inducing immunogenic cell death and activating innate immunity. Concurrently, ICIs enhance adaptive immunity by reversing T-cell exhaustion and expanding T-cell diversity. Clinical trials in melanoma, head and neck cancer and breast cancer showed superior efficacy. The Objective Response Rate (ORR) of combination therapy was 39%–62%, while the ORR of ICI monotherapy was 18%. Treatment heterogeneity is mainly attributed to virus-related factors, including targeting specificity and replication efficiency, tumor characteristics, such as antigen presenting ability and mutation load, and host immune status, including pre-existing antiviral antibodies and microbiome composition. This combined approach represents a paradigm shift in cancer immunotherapy, which effectively transforms immune “cold” tumors into “hot” tumors through the continuous activation of innate and adaptive immune responses. In the future, it is expected to improve the therapeutic effect of treatment-resistant malignant tumors through the integration of immune regulatory molecules, accurate biomarkers to guide the treatment scheme and triple combination strategy by a new generation of engineering viruses.

19 October 2022 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
HCHuijun Cao
Huijun Cao
ZWZhiqiang Wang
Zhiqiang Wang
YWYing Wang
Ying Wang
LYLijuan Ye
Lijuan Ye
RLRuilei Li
Ruilei Li
CGChunLei Ge
ChunLei Ge
Protein phosphatase 1 (PP1) inhibitors play a role in tumor progression through different mechanisms. Protein phosphatase 1 regulatory subunit 14D (PPP1R14D) is an inhibitor of PP1. However, the role of PPP1R14D in tumors and its mechanism of action are largely unknown. The purpose of the present study was to investigate the expression, function and mechanism of PPP1R14D in lung adenocarcinoma (LUAD). In the present study, GEPIA database analysis and immunohistochemistry demonstrated that PPP1R14D was highly expressed in LUAD tissues and that the expression of PPP1R14D in LUAD was negatively correlated with the age of patients and positively correlated with the 8th American Joint Committee on Cancer staging among patients. In addition, Kaplan‑Meier Plotter database analysis showed that PPP1R14D expression was associated with lower survival rates in patients with LUAD. PPP1R14D knockdown significantly inhibited LUAD cell proliferation, migration and invasion and induced LUAD cell arrest at the G1 phase of the cell cycle. Mechanistic analyses revealed that PPP1R14D knockdown may inhibit cell proliferation, migration and invasion by inactivating PKCα/BRAF/MEK/ERK pathway signaling and its downstream key proteins c‑Myc/Cyclin E1‑CDK2 and MMP2/MMP9/Vimentin. Moreover, knockdown of PPP1R14D suppressed tumor growth in vivo. All these results showed that PPP1R14D plays an important role in LUAD tumorigenesis and may serve as a potential prognostic factor and therapeutic target in LUAD.

16 May 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
TLTao Li
Tao Li
LLLing Liu
Ling Liu
LLLi Li
Li Li
XYXiaoxuan Yao
Xiaoxuan Yao
XHXiaoyuan Hu
Xiaoyuan Hu
HYHong Yao
Hong Yao
The combination of anti-angiogenesis agents with immune-checkpoint inhibitors is a promising treatment for patients with advanced hepatocellular carcinoma (HCC); however, therapeutic resistance caused by cancer stem cells present in tumor microenvironments remains to be overcome. In this study, we report for the first time that the Kringle 1 domain of human hepatocyte growth-factor α chain (HGFK1), a previously described anti-angiogenesis peptide, repressed the sub-population of CD90+ cancer stem cells (CSCs) and promoted their differentiation and chemotherapy sensitivity mainly through downregulation of pre-Met protein expression and inhibition of Wnt/β-catenin and Notch pathways. Furthermore, we showed that the i.p. injection of PH1 (a tumor-targeted and biodegradable co-polymer), medicated plasmids encoding Endostatin (pEndo), HGFK1 genes (pEndo), and a combination of 50% pEndo + 50% pHGFK1 all significantly suppressed tumor growth and prolonged the survival of the HCC-bearing mice. Importantly, the combined treatment produced a potent synergistic effect, with 25% of the mice showing the complete clearance of the tumor via a reduction in the microvessel density (MVD) and the number of CD90+ CSCs in the tumor tissues. These results suggest for the first time that HGFK1 inhibits the CSCs of HCC. Furthermore, the combination of two broad-spectrum anti-angiogenic factors, Endo and HGFK1, is the optimal strategy for the development of effective anti-HCC drugs.

1 January 2025 in Oncology Research
Verified
Journal Article
Open access
PDF file
FLFangyuan Li
Fangyuan Li
XHXiaoyuan Hu
Xiaoyuan Hu
XGXiaoge Gao
Xiaoge Gao
LLLing Liu
Ling Liu
TLTao Li
Tao Li
HYHong Yao
Hong Yao
Background: Liver cancer stem cells (LCSCs) are recognized as pivotal drivers of hepatocellular carcinoma (HCC) progression; however, the molecular mechanisms maintaining their stem-like phenotype remain largely unresolved. This work investigates the role of prefoldin subunit 6-like protein (PFDN6L) in shaping LCSC traits and promoting or restraining HCC progression. Methods: PFDN6L, a cytoskeleton-associated chaperone, was studied using multiple in vitro assays—cell growth evaluation, cell cycle profiling, and spheroid culture—alongside analyses of stemness-associated markers (SOX2, CD133, CD44). Tumorigenic capacity was assessed in xenograft mouse models, and signaling pathway interrogation was performed to define underlying mechanisms. Results: In patient samples, higher PFDN6L expression correlated with improved survival outcomes. Forced expression of PFDN6L induced G2/M arrest, diminished sphere formation, and reduced pluripotency marker expression, whereas knockdown accelerated in vivo tumor formation. Mechanistic experiments demonstrated that PFDN6L suppresses malignancy by simultaneously dampening AKT and ERK1/2 activation, thereby impairing oncogenic signaling cascades. Conclusion: PFDN6L acts as a negative regulator of LCSC-driven tumorigenesis. Its dual blockade of AKT and ERK pathways forms the mechanistic basis of its tumor-suppressive action, supporting its potential as a prognostic biomarker and therapeutic target in HCC.

1 July 2025 in Discover Oncology
Verified
Journal Article
Open access
GLGuicai Liang
Guicai Liang
LWLyubo Wang
Lyubo Wang
ZWZhiqiang Wang
Zhiqiang Wang
TLTao Li
Tao Li
LJLei Jiang
Lei Jiang
CGChunLei Ge
ChunLei Ge
There is a causal relationship between many non-communicable diseases and other infectious diseases. However, the exact relationship between lung cancer and the immune response to antibodies associated with viral diseases is unclear. Compared with other traditional methods, Mendelian randomization (MR) studies reduce the influence of confounding factors, thus improving the accuracy of the results. This study used MR to investigate the relationship between lung cancer and its subtypes, and the antibody immune response. A two-sample MR method was employed to examine the association between lung cancer, its subtypes, and antibody-mediated immunity linked to 46 infectious diseases. The instrumental variables were single nucleotide polymorphisms associated with lung cancer and its subtypes. Various MR methods were used to study the causal relationship between lung cancer risk and exposure, including weighted median, MR-Egger regression, inverse variance weighting, simple model and simple median methods. In addition, immunocytological analyses were performed on lung cancer and its subtypes. This study investigated the relationship between lung cancer and antibodies to varicella zoster glycoproteins I and E. This indicates that the level of these antibodies is a risk factor for lung cancer. The levels of antibodies to human herpes virus 7 U14, varicella zoster virus glycoproteins I and E, and anti-polyoma virus 2 were found to be related to squamous cell carcinoma, indicating a risk factor for lung cancer. Furthermore, the antibody levels of Epstein-Barr virus EBNA1 and Epstein-Barr virus VCA p18 were found to be related to lung squamous cell carcinoma and act as a protective factor. Another causal relationship was noted between small cell lung cancer and Epstein-Barr virus ZEBRA antibody levels, identifying ZEBRA as a risk factor. Leave-one-out sensitivity analysis and pleiotropy tests confirmed the stability of the results. Meanwhile, differences in the distribution of immune cells between different lung cancer subtypes provide further support for the MR results. This study established a causal relationship between infectious disease-related antibody immune responses and lung cancer and its subtypes via genetic methods, increasing the understanding of the role of infectious disease-related antibody immune responses in lung cancer.